Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been given an average rating of “Buy” by the six ratings firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $38.00.

ENTA has been the topic of a number of recent research reports. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 11th. ValuEngine raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. Robert W. Baird lifted their price target on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 8th. Finally, JMP Securities raised shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target on the stock in a research report on Tuesday, July 11th.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 2.31% during trading on Wednesday, hitting $43.50. 120,256 shares of the stock were exchanged. The stock’s 50 day moving average price is $38.05 and its 200-day moving average price is $32.98. Enanta Pharmaceuticals has a one year low of $21.52 and a one year high of $44.69. The company’s market cap is $830.42 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. The firm had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. Enanta Pharmaceuticals’s revenue was down 46.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.06) earnings per share. On average, analysts predict that Enanta Pharmaceuticals will post $0.90 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of ENTA. Mason Street Advisors LLC boosted its position in Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the last quarter. GAM Holding AG purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $108,000. Municipal Employees Retirement System of Michigan boosted its position in Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after buying an additional 110 shares during the last quarter. SG Americas Securities LLC boosted its position in Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 237 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,702 shares during the last quarter. 66.07% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Enanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of “Buy” by Brokerages” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/30/enanta-pharmaceuticals-inc-enta-given-average-recommendation-of-buy-by-brokerages.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.